UCB SA

Research UCB SA (0NZT) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

• Ticker0NZT
• ExchangeLSE
• CountryBelgium
• CurrencyEUR
• Financial periodFY2024
• RevenueEUR 6.15B
• Revenue growth17.1%
• Net incomeEUR 1.07B
• Free cash flowEUR 1.01B
• Gross margin71.5%

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome.

Frequently asked questions

What does UCB SA do?

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.